Gut metabolite ImP linked to accelerated cognitive decline

Recent research from the University of Wisconsin–Madison and UCLA suggests a significant link between gut microbiome metabolites and accelerated cognitive decline. A key focus is imidazole propionate (ImP), a bacterial metabolite produced in the digestive system.

Studies published in Nature Communications and eBioMedicine indicate that higher levels of ImP in the blood are associated with Alzheimer’s disease biomarkers and faster cognitive deterioration. In animal models, ImP was found to increase the accumulation of beta-amyloid and tau proteins, which are primary hallmarks of neurodegenerative diseases, and may impair the blood-brain barrier.

Additionally, a UCLA study involving approximately 1,500 adults found that a higher ‘Brain Aging Index’—a marker of biological brain age—correlated with poorer working memory, weakened executive function, and increased depressive symptoms. This index also showed correlations with specific gut bacteria and metabolic products. While these findings identify ImP as a potential molecular target for future prevention or treatment, researchers emphasize that current evidence does not yet support ImP reduction as an established therapy.